AUAUniversity Podcast Series: Episode No. 14

AUA2019 048IC Novel Agents & Concepts In The Management Of Hormone Naïve & CRPC

Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme

This course will include short didactic lectures followed by case presentations to give attendees an understanding of the many new FDA-approved agents, as well as existing standard therapies, for advanced prostate cancer-both non-metastatic and metastatic CRPC. Particular attention will be devoted to sequencing the new agents and positioning them as compared to older existing therapies. The cost effectiveness of new and existing agents will also be addressed.

Learning Objectives:

• 诊断非转移性和转移性阉割抵抗性前列腺癌(nmCRPC, mCRPC)，并有治疗的工作知识和适当的管理顺序。
• Manage nm and mCRPC with systemic agents by learning the proper candidates for treatment and be able to counsel patients on the pros and cons of therapy.
• Analyze the mechanism of action and risks/benefits of using systemic agents in the treatment of nm/mCRPC.
• Describe the bone-targeted, radiopharmaceutical agent and its sequencing.
• 综述新一代抗雄激素药物及其在nmCRPC和mCRPC中的应用。